Inventiva S.A. (IVEVF) Stock Analysis

Inventiva S.A. (IVEVF) Healthcare & Pipeline Overview

Inventiva S.A. is a clinical-stage biopharmaceutical company specializing in oral small molecule therapies for diseases like MASH and mucopolysaccharidoses. Their lead drug, Lanifibranor, is currently in Phase 3 clinical trials. With a focus on unmet medical needs, Inventiva operates primarily in France and internationally, holding promise in the competitive biotechnology sector.

What Is the Investment Thesis for IVEVF?

Positive trial outcomes could drive significant value, given the large and growing MASH market. The company's focus on oral small molecule therapies offers advantages in terms of patient compliance and manufacturing scalability. However, the company's reliance on Lanifibranor introduces concentration risk, and clinical trial outcomes are inherently uncertain. With a market cap of $848M and negative free cash flow, successful commercialization of Lanifibranor is critical for long-term sustainability. The company's gross margin of 95.2% suggests strong pricing power if the drug is approved.

Based on FMP financials and quantitative analysis

IVEVF Key Highlights

Lanifibranor, Inventiva's lead drug candidate, is currently in the NATiV3 Phase 3 clinical trial for the treatment of MASH, a significant milestone in its development.

• Inventiva has a high gross margin of 95.2%, indicating strong potential profitability upon successful commercialization of its products.
• The company's focus on oral small molecule therapies offers advantages in terms of patient compliance and ease of manufacturing.
• Inventiva's pipeline includes Odiparcil for mucopolysaccharidoses, addressing a rare disease with limited treatment options.
• The company's beta of 0.92 suggests that the stock price is slightly less volatile than the overall market.

Who Are IVEVF's Competitors?

IVEVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IVEVF's Key Strengths?

Novel pan-PPAR agonist Lanifibranor.

• Focus on unmet medical needs.
• Experienced management team.
• Strong intellectual property position.

What Are IVEVF's Weaknesses?

Reliance on Lanifibranor.

• Limited financial resources.
• Dependence on clinical trial outcomes.
• OTC market listing.

What Could Drive IVEVF Stock Higher?

NATiV3 Phase 3 clinical trial results for Lanifibranor in MASH.

• Potential partnerships or collaborations with larger pharmaceutical companies.
• Advancement of pipeline programs, including Odiparcil and TGF-ß.
• Regulatory approvals for Lanifibranor in key markets.
• Expansion into new therapeutic areas and geographic markets.

What Are the Key Risks for IVEVF?

Financial-distress signal — its Altman Z-Score of -2.60 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 5 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for Lanifibranor or other drug candidates.
• Competition from larger pharmaceutical companies with greater resources.
• Regulatory hurdles and delays in securing approvals.
• Reliance on Lanifibranor as the primary value driver.
• Limited financial resources and dependence on external funding.

What Are the Growth Opportunities for IVEVF?

• Expansion into new therapeutic areas: Inventiva has the opportunity to leverage its expertise in oral small molecule therapies to develop treatments for other metabolic and fibrotic diseases. This could involve expanding its pipeline through internal research and development or through strategic acquisitions and partnerships. The market for fibrotic diseases, such as idiopathic pulmonary fibrosis, is estimated to be substantial, offering significant growth potential. Timeline: 3-5 years.
• Geographic expansion: Inventiva currently operates primarily in France and internationally. Expanding its geographic footprint into new markets, such as the United States and Asia, could drive significant revenue growth. This would require establishing a commercial infrastructure and securing regulatory approvals in these new markets. The US market represents a particularly attractive opportunity, given its large size and favorable reimbursement environment. Timeline: 2-4 years.
• Strategic partnerships and collaborations: Inventiva can accelerate its growth by forming strategic partnerships and collaborations with larger pharmaceutical companies. This could involve licensing its drug candidates, co-developing new therapies, or collaborating on clinical trials. Such partnerships can provide access to additional funding, expertise, and commercial infrastructure. Timeline: Ongoing.
• Advancement of pipeline programs: Inventiva's pipeline includes Odiparcil for mucopolysaccharidoses and TGF-ß for idiopathic pulmonary fibrosis. Advancing these programs through clinical development and securing regulatory approvals could create significant value. The market for rare diseases, such as mucopolysaccharidoses, is characterized by high unmet medical needs and premium pricing. Timeline: 3-7 years.
• Data exclusivity and patent protection: Inventiva can protect its intellectual property and maintain a competitive advantage by securing data exclusivity and patent protection for its drug candidates. This can prevent competitors from developing and commercializing similar therapies for a certain period of time. Strong intellectual property protection is particularly important in the biotechnology industry, where innovation is highly valued. Timeline: Ongoing.

What Are IVEVF's Competitive Advantages?

• Patent protection for novel drug candidates.
• Data exclusivity for approved therapies.
• Expertise in oral small molecule drug development.
• Established relationships with key opinion leaders.
• First-mover advantage in specific therapeutic areas.

What Does IVEVF Do?

Inventiva S.A., founded in 2011 and headquartered in Daix, France, is a clinical-stage biopharmaceutical company dedicated to developing innovative oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as metabolic dysfunction-associated steatohepatitis (MASH) and mucopolysaccharidoses. Inventiva's lead product candidate is Lanifibranor, a novel pan-peroxisome proliferator-activated receptor (PPAR) agonist. Lanifibranor is currently undergoing the NATiV3 Phase 3 clinical trial for the treatment of adult patients with MASH, a severe form of non-alcoholic fatty liver disease. In addition to Lanifibranor, Inventiva is developing Odiparcil for the treatment of patients with mucopolysaccharidoses (MPS), a group of rare genetic disorders. The company also has a pre-clinical program, TGF-ß, targeting idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. Inventiva's strategy involves identifying and developing differentiated drug candidates with the potential to improve the lives of patients with limited treatment options. The company operates primarily in France and internationally, seeking to establish partnerships and collaborations to advance its pipeline and expand its market reach. With a team of 84 employees, Inventiva is committed to scientific innovation and clinical excellence in the pursuit of novel therapies.

What Products and Services Does IVEVF Offer?

• Develop oral small molecule therapies.
• Focus on treating metabolic dysfunction-associated steatohepatitis (MASH).
• Develop treatments for mucopolysaccharidoses.
• Research therapies for idiopathic pulmonary fibrosis.
• Conduct clinical trials to evaluate drug efficacy and safety.
• Seek regulatory approvals for new therapies.
• Commercialize approved therapies.

How Does IVEVF Make Money?

• Develop and patent novel drug candidates.
• Conduct clinical trials to demonstrate efficacy and safety.
• Seek regulatory approval from health authorities.
• Commercialize approved drugs directly or through partnerships.
• Generate revenue through drug sales and licensing agreements.

What Industry Does IVEVF Operate In?

Inventiva operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The MASH market, which Lanifibranor targets, is estimated to be a multi-billion dollar market with substantial unmet medical needs. Key trends in the industry include the development of personalized medicine, the increasing importance of biomarkers, and the growing adoption of digital health technologies. Inventiva competes with larger pharmaceutical companies and specialized biotech firms in the development of MASH therapies. The company's success depends on its ability to demonstrate clinical efficacy, secure regulatory approvals, and establish a strong market presence.

Who Are IVEVF's Key Customers?

• Patients suffering from MASH.
• Patients with mucopolysaccharidoses.
• Patients with idiopathic pulmonary fibrosis.
• Healthcare providers who prescribe Inventiva's therapies.
• Pharmaceutical companies that may partner with Inventiva.

Company Profile

Inventiva S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Daix, FR. The company is led by CEO Andrew Obenshain. IVEVF has traded publicly since 2019.

Inventiva S.A. Financial Trajectory

Inventiva S.A. (IVEVF) reported $34K in revenue for Q4 FY2025, a decline of 99.5% compared to the prior quarter. The company recorded a net loss of $206.7M, with diluted EPS of $-0.32. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, IVEVF averaged $-1.40 in diluted EPS.

How Inventiva S.A. Is Valued

Inventiva S.A. carries a market capitalization of $848M, placing it in the small-cap category.

Key Financial Metrics

Its free cash flow yield is -10.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.1%, the inverse of the P/E and a quick read on earnings relative to price.

Inventiva S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.60 places it in the distress zone, a signal of elevated financial risk.

Inventiva S.A. has missed Wall Street's EPS estimate in 4 of its last 5 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 105.3% below estimates on average.

Wall Street analysts project Inventiva S.A. revenue of about $6.6M for fiscal 2026, with EPS near $-0.66. The estimate reflects 11 contributing analysts.

IVEVF Financials

IVEVF Latest News

IVEVF Analyst Consensus

IVEVF MoonshotScore

Common Questions About IVEVF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources